190 related articles for article (PubMed ID: 23845572)
21. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
[TBL] [Abstract][Full Text] [Related]
22. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
23. Controversies in clinicopathological characteristics and treatment strategies of male breast cancer: A review of the literature.
Losurdo A; Rota S; Gullo G; Masci G; Torrisi R; Bottai G; Zuradelli M; Gatzemeier W; Santoro A
Crit Rev Oncol Hematol; 2017 May; 113():283-291. PubMed ID: 28427518
[TBL] [Abstract][Full Text] [Related]
24. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
25. Male breast cancer: a special therapeutic problem. Anything new? (Review).
Gennari R; Curigliano G; Jereczek-Fossa BA; Zurrida S; Renne G; Intra M; Galimberti V; Luini A; Orecchia R; Viale G; Goldhrisch A; Veronesi U
Int J Oncol; 2004 Mar; 24(3):663-70. PubMed ID: 14767551
[TBL] [Abstract][Full Text] [Related]
26. Male breast cancer; analysis of 58 cases in Shiraz, South of Iran.
Tahmasebi S; Akrami M; Omidvari S; Salehi A; Talei A
Breast Dis; 2010; 31(1):29-32. PubMed ID: 20644250
[TBL] [Abstract][Full Text] [Related]
27. Male breast cancer: management and follow-up recommendations.
Kiluk JV; Lee MC; Park CK; Meade T; Minton S; Harris E; Kim J; Laronga C
Breast J; 2011; 17(5):503-9. PubMed ID: 21883641
[TBL] [Abstract][Full Text] [Related]
28. Treatment of breast cancer.
Maughan KL; Lutterbie MA; Ham PS
Am Fam Physician; 2010 Jun; 81(11):1339-46. PubMed ID: 20521754
[TBL] [Abstract][Full Text] [Related]
29. Platinum compounds in the treatment of advanced breast cancer.
Martín M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
30. Intracystic papillary carcinoma of the breast: An in situ or invasive tumor? Results of immunohistochemical analysis and clinical follow-up.
Wynveen CA; Nehhozina T; Akram M; Hassan M; Norton L; Van Zee KJ; Brogi E
Am J Surg Pathol; 2011 Jan; 35(1):1-14. PubMed ID: 21084964
[TBL] [Abstract][Full Text] [Related]
31. Clinical trials update: Medical management of advanced breast cancer.
Major MA
Cancer Nurs; 2003 Dec; 26(6 Suppl):10S-15S. PubMed ID: 15025407
[TBL] [Abstract][Full Text] [Related]
32. High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: a retrospective chart review.
Mahtani RL; Stein A; Vogel CL
Clin Ther; 2009; 31 Pt 2():2371-8. PubMed ID: 20110046
[TBL] [Abstract][Full Text] [Related]
33. [Effective treatment strategy in elderly breast cancer patients].
Boér K
Orv Hetil; 2005 Jan; 146(1):15-21. PubMed ID: 15715368
[TBL] [Abstract][Full Text] [Related]
34. Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment.
Milgrom S; Cody H; Tan L; Morrow M; Pesce C; Setton J; Rogers K; Arnold B; Eaton A; Catalano J; McCormick B; Powell S; Ho A
Ann Surg Oncol; 2012 Nov; 19(12):3762-70. PubMed ID: 22576064
[TBL] [Abstract][Full Text] [Related]
35. Epidemiology and practice patterns for male breast cancer compared with female breast cancer in Japan.
Ishii T; Nakano E; Watanabe T; Higashi T
Cancer Med; 2020 Aug; 9(16):6069-6075. PubMed ID: 32613775
[TBL] [Abstract][Full Text] [Related]
36. Male breast cancer.
Reis LO; Dias FG; Castro MA; Ferreira U
Aging Male; 2011 Jun; 14(2):99-109. PubMed ID: 21204612
[TBL] [Abstract][Full Text] [Related]
37. Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer.
Gligorov J; Lotz JP
Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():53-66. PubMed ID: 19101794
[TBL] [Abstract][Full Text] [Related]
38. Breast cancer in very young women.
Liukkonen S; Leidenius M; Saarto T; Sjöström-Mattson J
Eur J Surg Oncol; 2011 Dec; 37(12):1030-7. PubMed ID: 21937191
[TBL] [Abstract][Full Text] [Related]
39. HER-2/neu expression in primary and metastatic breast cancer.
Lower EE; Glass E; Blau R; Harman S
Breast Cancer Res Treat; 2009 Jan; 113(2):301-6. PubMed ID: 18273700
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant therapy for breast cancer.
NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
